This trial is testing two different types of monotherapy (single treatment) for advanced or metastatic solid tumors. Part A is testing compound DCBY02 while Part B is testing compound DCSZ11 (which is not yet active).
4 Primary · 22 Secondary · Reporting Duration: 2 years
192 Total Participants · 4 Treatment Groups
Primary Treatment: Part 2B Dose Expansion · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: